Cell technologies have provided promising tools for modulating the properties of multipotent mesenchymal stem/stromal cells (MSCs) to meet the needs of cell therapy as well as tissue engineering and regenerative medicine (TERM). Ex vivo preconditioning is directed at enhancing the engraftment of MSCs and activating their secretory activity, primarily the production of soluble mediators. The present review aims to highlight the underestimated effect of the most accepted preconditioning approaches on the modification of the important set of insoluble molecules secreted by MSCs into extracellular space—the extracellular matrix (ECM). A thorough review of the published literature was performed, with particular emphasis on ECM-related data. The analysis of data on ECM changes showed that most of the applied preconditioning methods—hypoxia, inflammatory priming, pharmacological agents, 3D culture, and scaffolds—generally stimulate ECM production, increase the deposition of growth factors, promote alignment, and increase ECM stiffness. There are already preliminary results demonstrating the successful application of preconditioned ECM for promoting angiogenesis, targeted stromal lineage differentiation, and other therapeutic goals. The prospects for further research in this area are discussed.

The expression of several genes which functions are associated with cellular senescence was analyzed in multipotent mesenchymal stromal cells during long-term cultivation at different oxygen levels (20, 5, and 1%) using the RT² Profiler™ PCR Array Human Cellular Senescence system (Qiagen, United States). It was established that replicative senescence processes develop most actively in the cells cultured under the standard conditions (20% O₂). The most significant changes were observed in the expression of CCND1, ID1, IGF1, PIK3CA, and SERPINE1 genes.